Verlängerung der Übergangsfrist zur Listung der sonstigen Produkte zur Wundbehandlung gemäß Anlage V der Arzneimittel-Richtlinie

This procedure is a written question regarding the extension of the transition period for listing other wound care products under Annex V of the Medicines Directive. It seeks clarification on the timeline and regulatory requirements for these products to be correctly categorized and listed. This affects pharmaceutical manufacturers and healthcare providers dealing with wound treatment products, as it impacts the legal deadlines for compliance with EU medicinal product guidelines.